Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.68 USD | -1.18% | -0.59% | -42.66% |
Apr. 11 | BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target | MT |
Apr. 02 | HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating | MT |
Financials (USD)
Sales 2024 * | 16.93M | Sales 2025 * | 13.83M | Capitalization | 69.79M |
---|---|---|---|---|---|
Net income 2024 * | -58M | Net income 2025 * | -69M | EV / Sales 2024 * | 4.12 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.05 x |
P/E ratio 2024 * |
-1.3
x | P/E ratio 2025 * |
-1.26
x | Employees | 107 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.27% |
1 day | -1.18% | ||
1 week | -0.59% | ||
Current month | -25.99% | ||
1 month | -31.15% | ||
3 months | -26.96% | ||
6 months | -41.36% | ||
Current year | -42.66% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 34 | 15-12-31 | |
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Richard Morris
DFI | Director of Finance/CFO | 51 | 21-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Sanford Zweifach
CHM | Chairman | 68 | 21-10-31 |
Director/Board Member | 66 | 22-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +2.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 1.68 | -1.18% | 50,359 |
24-04-23 | 1.7 | -9.09% | 135,661 |
24-04-22 | 1.87 | +14.72% | 144,126 |
24-04-19 | 1.63 | -4.68% | 257,375 |
24-04-18 | 1.71 | +1.18% | 174,528 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.66% | 70.62M | |
-1.51% | 105B | |
+3.22% | 97.5B | |
+1.86% | 22.19B | |
-16.53% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.09% | 14.52B | |
+5.47% | 14.09B | |
+28.85% | 10.99B |
- Stock Market
- Equities
- CARM Stock